3wjl › Citations

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).

Fig. 1.
Fig. 2.
Fig. 3.
Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M, Wada Y, Haraya K, Miyazaki T, Hattori K
OpenAccess logo Protein Eng Des Sel 26 589-98 (2013)
Cited: 66 times
EuropePMC logo PMID: 23744091

Abstract

Engaging inhibitory FcγRIIb by Fc region has been recently reported to be an attractive approach for improving the efficacy of antibody therapeutics. However, the previously reported S267E/L328F variant with enhanced binding affinity to FcγRIIb, also enhances binding affinity to FcγRIIa(R131) allotype to a similar degree because FcγRIIb and FcγRIIa(R131) are structurally similar. In this study, we applied comprehensive mutagenesis and structure-guided design based on the crystal structure of the Fc/FcγRIIb complex to identify a novel Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). This novel variant has more than 200-fold stronger binding affinity to FcγRIIb than wild-type IgG1, while binding affinity to FcγRIIa(R131) and FcγRIIa(H131) is comparable with or lower than wild-type IgG1. This selectivity was achieved by conformational change of the C(H)2 domain by mutating Pro to Asp at position 238. Fc variant with increased binding to both FcγRIIb and FcγRIIa induced platelet aggregation and activation in an immune complex form in vitro while our novel variant did not. When applied to agonistic anti-CD137 IgG1 antibody, our variant greatly enhanced the agonistic activity. Thus, the selective enhancement of FcγRIIb binding achieved by our Fc variant provides a novel tool for improving the efficacy of antibody therapeutics.

Articles - 3wjl mentioned but not cited (2)

  1. Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality. Tam SH, McCarthy SG, Armstrong AA, Somani S, Wu SJ, Liu X, Gervais A, Ernst R, Saro D, Decker R, Luo J, Gilliland GL, Chiu ML, Scallon BJ. Antibodies (Basel) 6 E12 (2017)
  2. Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer. Chabrol E, Fagnen C, Landron S, Marcheteau E, Stojko J, Guenin SP, Antoine M, Fould B, Ferry G, Boutin JA, Vénien-Bryan C. Protein Sci 30 1946-1957 (2021)


Reviews citing this publication (36)

  1. Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Carter PJ, Lazar GA. Nat Rev Drug Discov 17 197-223 (2018)
  2. Mouse and human FcR effector functions. Bruhns P, Jönsson F. Immunol Rev 268 25-51 (2015)
  3. IgG Fc engineering to modulate antibody effector functions. Wang X, Mathieu M, Brezski RJ. Protein Cell 9 63-73 (2018)
  4. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Saunders KO. Front Immunol 10 1296 (2019)
  5. The promise and challenges of immune agonist antibody development in cancer. Mayes PA, Hance KW, Hoos A. Nat Rev Drug Discov 17 509-527 (2018)
  6. Antibody Structure and Function: The Basis for Engineering Therapeutics. Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibodies (Basel) 8 E55 (2019)
  7. Human IgG4: a structural perspective. Davies AM, Sutton BJ. Immunol Rev 268 139-159 (2015)
  8. Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? Marshall MJE, Stopforth RJ, Cragg MS. Front Immunol 8 1245 (2017)
  9. OX40: Structure and function - What questions remain? Willoughby J, Griffiths J, Tews I, Cragg MS. Mol Immunol 83 13-22 (2017)
  10. Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment. Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Antibodies (Basel) 9 E64 (2020)
  11. Boosting therapeutic potency of antibodies by taming Fc domain functions. Kang TH, Jung ST. Exp Mol Med 51 1-9 (2019)
  12. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Yu J, Song Y, Tian W. J Hematol Oncol 13 45 (2020)
  13. Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life. Saxena A, Wu D. Front Immunol 7 580 (2016)
  14. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. Caaveiro JM, Kiyoshi M, Tsumoto K. Immunol Rev 268 201-221 (2015)
  15. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Igawa T, Haraya K, Hattori K. Immunol Rev 270 132-151 (2016)
  16. Harnessing Fc receptor biology in the design of therapeutic antibodies. Sondermann P, Szymkowski DE. Curr Opin Immunol 40 78-87 (2016)
  17. A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Hanson QM, Barb AW. Biochemistry 54 2931-2942 (2015)
  18. Immunoglobulin isotype knowledge and application to Fc engineering. Brezski RJ, Georgiou G. Curr Opin Immunol 40 62-69 (2016)
  19. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs. Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P. Immunol Cell Biol 98 287-304 (2020)
  20. Glycosylation of IgG-Fc: a molecular perspective. Kiyoshi M, Tsumoto K, Ishii-Watabe A, Caaveiro JMM. Int Immunol 29 311-317 (2017)
  21. Structural mechanism of high affinity FcγRI recognition of immunoglobulin G. Lu J, Sun PD. Immunol Rev 268 192-200 (2015)
  22. The Highly Evolvable Antibody Fc Domain. Park HI, Yoon HW, Jung ST. Trends Biotechnol 34 895-908 (2016)
  23. Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. Boesch AW, Alter G, Ackerman ME. Curr Opin HIV AIDS 10 160-169 (2015)
  24. Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies. Barnhart BC, Quigley M. Immunol Cell Biol 95 340-346 (2017)
  25. Avidity in antibody effector functions and biotherapeutic drug design. Oostindie SC, Lazar GA, Schuurman J, Parren PWHI. Nat Rev Drug Discov 21 715-735 (2022)
  26. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Ryan JM, Wasser JS, Adler AJ, Vella AT. Expert Opin Biol Ther 16 655-674 (2016)
  27. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities. Waight JD, Gombos RB, Wilson NS. Hum Antibodies 25 87-109 (2017)
  28. Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations. Delidakis G, Kim JE, George K, Georgiou G. Annu Rev Biomed Eng 24 249-274 (2022)
  29. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. Jhajj HS, Lwo TS, Yao EL, Tessier PM. Trends Mol Med 29 48-60 (2023)
  30. The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection. Farouq MAH, Acevedo R, Ferro VA, Mulheran PA, Al Qaraghuli MM. Int J Mol Sci 23 6078 (2022)
  31. The Role of Bispecific Antibodies in Non-Hodgkin's Lymphoma: From Structure to Prospective Clinical Use. Tavarozzi R, Manzato E. Antibodies (Basel) 11 16 (2022)
  32. Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects. Nawab DH. Hum Vaccin Immunother 17 5532-5545 (2021)
  33. Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies. Adams R, Osborn G, Mukhia B, Laddach R, Willsmore Z, Chenoweth A, Geh JLC, MacKenzie Ross AD, Healy C, Barber L, Tsoka S, Sanz-Moreno V, Lacy KE, Karagiannis SN. Oncoimmunology 11 2127284 (2022)
  34. Development of Effective Siglec-9 Antibodies Against Cancer. Wang JHS, Jiang N, Jain A, Lim J. Curr Oncol Rep 25 41-49 (2023)
  35. Next generation of multispecific antibody engineering. Keri D, Walker M, Singh I, Nishikawa K, Garces F. Antib Ther 7 37-52 (2024)
  36. [Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies]. Ishii-Watabe A, Tada M, Suzuki T, Kawasaki N. Yakugaku Zasshi 135 857-866 (2015)

Articles citing this publication (28)

  1. Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Proc Natl Acad Sci U S A 112 833-838 (2015)
  2. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Cancer Cell 29 820-831 (2016)
  3. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Bournazos S, Corti D, Virgin HW, Ravetch JV. Nature 588 485-490 (2020)
  4. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. Zhang D, Goldberg MV, Chiu ML. J Biol Chem 291 27134-27146 (2016)
  5. Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering. Iwayanagi Y, Igawa T, Maeda A, Haraya K, Wada NA, Shibahara N, Ohmine K, Nambu T, Nakamura G, Mimoto F, Katada H, Ito S, Tachibana T, Jishage K, Hattori K. J Immunol 195 3198-3205 (2015)
  6. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs. Boesch AW, Miles AR, Chan YN, Osei-Owusu NY, Ackerman ME. MAbs 9 455-465 (2017)
  7. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Liu X, Zhao Y, Shi H, Zhang Y, Yin X, Liu M, Zhang H, He Y, Lu B, Jin T, Li F. Nat Commun 10 4206 (2019)
  8. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization. Zhang D, Armstrong AA, Tam SH, McCarthy SG, Luo J, Gilliland GL, Chiu ML. MAbs 9 1129-1142 (2017)
  9. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. Maeda A, Iwayanagi Y, Haraya K, Tachibana T, Nakamura G, Nambu T, Esaki K, Hattori K, Igawa T. MAbs 9 844-853 (2017)
  10. A general Fc engineering platform for the next generation of antibody therapeutics. Chen D, Zhao Y, Li M, Shang H, Li N, Li F, Wang W, Wang Y, Jin R, Liu S, Li X, Gao S, Tian Y, Li R, Li H, Zhang Y, Du M, Cao Y, Zhang Y, Li X, Huang Y, Hu LA, Li F, Zhang H. Theranostics 11 1901-1917 (2021)
  11. Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands. Boesch AW, Kappel JH, Mahan AE, Chu TH, Crowley AR, Osei-Owusu NY, Alter G, Ackerman ME. Biotechnol Bioeng 115 1265-1278 (2018)
  12. Domain binding and isotype dictate the activity of anti-human OX40 antibodies. Griffiths J, Hussain K, Smith HL, Sanders T, Cox KL, Semmrich M, Mårtensson L, Kim J, Inzhelevskaya T, Penfold CA, Tutt AL, Mockridge CI, Chan HC, English V, French RF, Teige I, Al-Shamkhani A, Glennie MJ, Frendeus BL, Willoughby JE, Cragg MS. J Immunother Cancer 8 e001557 (2020)
  13. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Huang Z, Pang X, Zhong T, Qu T, Chen N, Ma S, He X, Xia D, Wang M, Xia M, Li B. Front Immunol 13 924542 (2022)
  14. Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering. van der Schoot JMS, Fennemann FL, Valente M, Dolen Y, Hagemans IM, Becker AMD, Le Gall CM, van Dalen D, Cevirgel A, van Bruggen JAC, Engelfriet M, Caval T, Bentlage AEH, Fransen MF, Nederend M, Leusen JHW, Heck AJR, Vidarsson G, Figdor CG, Verdoes M, Scheeren FA. Sci Adv 5 eaaw1822 (2019)
  15. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Heckel F, Turaj AH, Fisher H, Chan HTC, Marshall MJE, Dadas O, Penfold CA, Inzhelevskaya T, Mockridge CI, Alvarado D, Tews I, Keler T, Beers SA, Cragg MS, Lim SH. Commun Biol 5 229 (2022)
  16. Characterization of Mauritian Cynomolgus Macaque FcγR Alleles Using Long-Read Sequencing. Haj AK, Arbanas JM, Yamniuk AP, Karl JA, Bussan HE, Drinkwater KY, Graham ME, Ericsen AJ, Prall TM, Moore K, Cheng L, Gao M, Graziano RF, Loffredo JT, Wiseman RW, O'Connor DH. J Immunol 202 151-159 (2019)
  17. FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody. Zhang D, Whitaker B, Derebe MG, Chiu ML. MAbs 10 463-475 (2018)
  18. Optimization of protein-protein docking for predicting Fc-protein interactions. Agostino M, Mancera RL, Ramsland PA, Fernández-Recio J. J Mol Recognit 29 555-568 (2016)
  19. Fcγ receptor-mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies. Rogel A, Ibrahim FM, Thirdborough SM, Renart-Depontieu F, Birts CN, Buchan SL, Preville X, King EV, Al-Shamkhani A. JCI Insight 7 e158444 (2022)
  20. Loop Grafting between Similar Local Environments for Fc-Silent Antibodies. Lešnik S, Hodošček M, Podobnik B, Konc J. J Chem Inf Model 60 5475-5486 (2020)
  21. Solution structure of deglycosylated human IgG1 shows the role of CH2 glycans in its conformation. Spiteri VA, Doutch J, Rambo RP, Gor J, Dalby PA, Perkins SJ. Biophys J 120 1814-1834 (2021)
  22. Antibody interfaces revealed through structural mining. Yin Y, Romei MG, Sankar K, Pal LR, Hoi KH, Yang Y, Leonard B, De Leon Boenig G, Kumar N, Matsumoto M, Payandeh J, Harris SF, Moult J, Lazar GA. Comput Struct Biotechnol J 20 4952-4968 (2022)
  23. Development of cell-based assay for predictively evaluating the FcγR-mediated human immune cell activation by therapeutic monoclonal antibodies. Takakura M, Tada M, Ishii-Watabe A. Biochem Biophys Res Commun 485 189-194 (2017)
  24. A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo. You M, Chen F, Yu C, Chen Y, Wang Y, Liu X, Guo X, Zhou B, Wang X, Zhang B, Fang M, Zhang T, Yue P, Wang Y, Yuan Q, Luo W. Front Pharmacol 14 1213726 (2023)
  25. Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement. Sampei Z, Koo CX, Teo FJ, Toh YX, Fukuzawa T, Gan SW, Nambu T, Ho A, Honda K, Igawa T, Ahmed F, Wang CI, Fink K, Nezu J. Antibodies (Basel) 12 36 (2023)
  26. Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering. Hori Y, Ohmine K, Katada H, Noguchi Y, Sato K, Nambu T, Adeline LR, Wan GS, Haraya K, Ozeki K, Nanami M, Tachibana T, Sampei Z, Kuramochi T, Nezu J, Hattori K, Igawa T. MAbs 14 2068213 (2022)
  27. FcγRI FG-loop functions as a pH sensitive switch for IgG binding and release. Lu J, Spencer M, Zou Z, Traver M, Brzostowski J, Sun PD. Front Immunol 14 1100499 (2023)
  28. Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing. Liang Y, Li X, Peng F, Ye X, Wang W, Cen T, Li F, Lu Y, Liu Z, Liu H, Ding K, Ye K, Yu Y, Ma T, Zhang S, Huang Y, Wang Y, Yang X, Fu R, Zhang H. Theranostics 12 7729-7744 (2022)


Quick links